Alphanine SD Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Alphanine SD market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to increased awareness of hemophilia management, a rise in the prevalence of hemophilia B, greater adoption of Factor IX concentrates, improvements in diagnostic technologies, and enhanced healthcare infrastructure.

The projected growth during the forecast period can be attributed to rising demand for safer and more effective clotting factor products, increasing preference for prophylactic treatments, a growing focus on personalized medicine, greater funding for rare bleeding disorders, and supportive regulatory frameworks. Key trends expected include the transition from plasma-derived to recombinant therapies, the integration of gene therapy in hemophilia treatment, the rising adoption of home-based care solutions, the increasing popularity of long-acting clotting factors, and the development of non-replacement therapies.

The growing prevalence of hemophilia is expected to propel the growth of the alphanine SD market moving forward. Hemophilia is a rare inherited bleeding disorder where the blood cannot clot properly due to deficiencies in clotting factors such as VIII or IX. The rising prevalence of hemophilia can be attributed to better diagnostic capabilities, enhanced awareness campaigns, improved healthcare infrastructure, and longer life expectancy resulting from advanced treatments. Alphanine SD provides targeted treatment for hemophilia B, improving patient outcomes and offering effective management for individuals with this condition. For example, in November 2022, the United Kingdom Hemophilia Centre Doctors’ Organisation (UKHCDO) reported an increase in new registrations of Hemophilia A, from 16 in 2021 to 19 in 2022. Therefore, the growing prevalence of hemophilia is driving the alphanine SD market.

The rise in healthcare expenditure is expected to fuel the growth of the alphanine SD market. Healthcare expenditure refers to the total spending on medical services, healthcare infrastructure, pharmaceuticals, and related activities. As healthcare costs increase due to an aging population, the prevalence of chronic diseases, advances in medical technology, and greater access to healthcare services, Alphanine SD contributes to rising healthcare expenditure through its prophylactic use and management of bleeding episodes in hemophilia B patients. For instance, according to Cross River Therapy, the U.S. pharmaceutical industry generated $550 billion in revenue in 2021, with projected spending on medicines expected to rise to $605-$635 billion by 2025. Thus, the increasing healthcare expenditure is driving the demand for alphanine SD.

The rising aging population is key factor expected to drive the growth of the alphanine SD market. The aging population refers to the growing number of individuals aged 65 and older, a result of higher life expectancy and lower birth rates. This demographic shift is fueled by advancements in healthcare, improved living conditions, and medical technology. Alphanine SD is crucial for managing bleeding disorders in older adults, as it helps mitigate issues related to blood clotting, improving overall health outcomes and enhancing quality of life. According to the Population Reference Bureau, the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, contributing to a higher demand for treatments like Alphanine SD. Therefore, the rising aging population is a driving force behind the growth of the Alphanine SD market.

Key player operating in the alphanine SD market is Grifols SA.

North America was the largest region in the alphanine SD market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the alphanine SD market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alphanine SD is a high-purity, freeze-dried Factor IX concentrate derived from human plasma, specifically designed to treat hemophilia B by replacing the deficient clotting factor. It is used to control and prevent bleeding episodes, manage perioperative bleeding, and provide routine prophylaxis for individuals with hemophilia B.

The main product types in the alphanine SD portfolio include plasma-derived Factor IX concentrates and recombinant Factor IX products. Plasma-derived Factor IX concentrates are purified products derived from blood plasma, used to treat Factor IX deficiencies. In the Alphanine SD market, these concentrates are effective in managing and treating bleeding disorders like hemophilia B. Available in formulations such as lyophilized powder and intravenous solutions, Alphanine SD is indicated for clinical applications including hemophilia B treatment, inhibitor management, bleeding episodes, and surgical prophylaxis. It is designed for use in adults, pediatric patients, and the geriatric population.

The alphanine SD market research report is one of a series of new reports that provides alphanine SD market statistics, including alphanine SD industry global market size, regional shares, competitors with a alphanine SD market share, detailed alphanine SD market segments, market trends and opportunities, and any further data you may need to thrive in the alphanine SD industry. This alphanine SD market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alphanine SD market consists of sales of infusion devices, dilution kits, and prophylactic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.